Journal of Clinical Oncology, Vol 1, 2-10, Copyright © 1983 by American Society of Clinical Oncology

ARTICLES

Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles

G Tancini, G Bonadonna, P Valagussa, S Marchini and U Veronesi

We report the 5-yr results of a prospective randomized study comparing 12 versus 6 cycles of CMF (cyclophosphamide, methotrexate, fluorouracil) with the aim to evaluate the possibility of reducing the duration of adjuvant treatment without compromising the therapeutic effect of the multimodal approach. At 5-yr from mastectomy, both relapse-free survival (CMF 12: 59%; CMF 6: 65.6%) and total survival (CMF 12: 72.7%; CMF 6: 76.9%) were not significantly different in the two treatment groups. Within the two series, no difference was detected between pre- and postmenopausal patients (CMF 12: 59.3% versus 57.6%; CMF 6: 66.5% versus 63.1%), while findings were inversely related to the number of involved axillary nodes. The analysis of relapse-free survival confirmed that in both menopausal groups, relapse-free survival was not significantly affected by estrogen receptor status. Acute toxic manifestations were moderate and reversible. In particular, no drug-induced leukemia nor increased incidence of solid tumors other than breast cancer were documented in this series. Present results after 12 CMF cycles are almost identical to those of our first CMF adjuvant study. Current findings are sufficiently mature to indicate that the maximum tumor cytoreduction with CMF occurs within a relatively short period of time. To improve the results achieved with a single multidrug regimen, more intensive forms of treatment, i.e., utilizing non-cross-resistant combinations, warrant careful evaluation.

Related Article

• Lessons From the Initial Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil Studies in Operable Breast Cancer
  Gianni Bonadonna, Pinuccia Valagussa, and Umberto Veronesi
  JCO 2008 26: 342-344 [Full Text]

This article has been cited by other articles:

				G. Bonadonna, P. Valagussa, and U. Veronesi Lessons From the Initial Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil Studies in Operable Breast Cancer J. Clin. Oncol., January 20, 2008; 26(3): 342 - 344. [Full Text] [PDF]

				P. Francis, J. Crown, A. Di Leo, M. Buyse, A. Balil, M. Andersson, B. Nordenskjold, I. Lang, R. Jakesz, D. Vorobiof, et al. Adjuvant Chemotherapy With Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02 98 Randomized Trial J Natl Cancer Inst, January 16, 2008; 100(2): 121 - 133. [Abstract] [Full Text] [PDF]

				G. Bonadonna, A. Moliterni, M. Zambetti, M. G. Daidone, S. Pilotti, L. Gianni, and P. Valagussa 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study BMJ, January 29, 2005; 330(7485): 217. [Abstract] [Full Text] [PDF]

				G. Bonadonna, M. Zambetti, A. Moliterni, L. Gianni, and P. Valagussa Clinical Relevance of Different Sequencing of Doxorubicin and Cyclophosphamide, Methotrexate, and Fluorouracil in Operable Breast Cancer J. Clin. Oncol., May 1, 2004; 22(9): 1614 - 1620. [Abstract] [Full Text] [PDF]

				M. Martin, A. Villar, A. Sole-Calvo, R. Gonzalez, B. Massuti, J. Lizon, C. Camps, A. Carrato, A. Casado, M. T. Candel, et al. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group Ann. Onc., June 1, 2003; 14(6): 833 - 842. [Abstract] [Full Text] [PDF]

				T. Petit, C. Borel, S. Theobald, D. Serin, J.-F. Rodier, G. Prevot, J.-P. Brettes, and T. Klein Randomized Multicentric Study of Perioperative Chemotherapy With Mitoxantrone in Early Breast Cancer Ann. Surg. Oncol., May 1, 2003; 10(4): 369 - 375. [Abstract] [Full Text] [PDF]

				P. Fumoleau, P. Kerbrat, P. Romestaing, P. Fargeot, A. Bremond, M. Namer, S. Schraub, M.-J. Goudier, J. Mihura, A. Monnier, et al. Randomized Trial Comparing Six Versus Three Cycles of Epirubicin-Based Adjuvant Chemotherapy in Premenopausal, Node-Positive Breast Cancer Patients: 10-Year Follow-Up Results of the French Adjuvant Study Group 01 Trial J. Clin. Oncol., January 15, 2003; 21(2): 298 - 305. [Abstract] [Full Text] [PDF]

				T. Morrow, M. Siegel, S. Boone, G. Lawless, and W. Carter Chemotherapy Dose Intensity Determination as a Quality of Care Measure for Managed Care Organizations in the Treatment of Early-Stage Breast Cancer American Journal of Medical Quality, November 1, 2002; 17(6): 218 - 224. [Abstract] [PDF]

				G. N Hortobagyi Progress in Systemic Chemotherapy of Primary Breast Cancer: an Overview J Natl Cancer Inst Monographs, December 1, 2001; 2001(30): 72 - 79. [Abstract] [Full Text] [PDF]

				C. A. Hudis and L. Norton Adjuvant Drug Treatment for Resectable Breast Cancer Oncologist, December 1, 1997; 2(6): 351 - 358. [Abstract] [Full Text] [PDF]

				E. FREI III Cancer Chemotherapy Science, April 15, 1983; 220(4594): 254 - 256. [PDF]